Major Depressive Disorder Clinical Trial
— EDPT-ADOSOfficial title:
Assessment of Transcultural Psychotherapy to Treat Major Depressive Disorder in Children and Adolescents From Migrant Families: a Bayesian Randomized Controlled Trial
The symptomatic and clinical expression of psychiatric disorders in children and adolescents
is strongly influenced by the cultural setting they are growing up in. These cultural
variations complicate psychiatric care, especially for migrant children, for whom appropriate
care must be designed.
Transcultural psychotherapy is an original psychotherapeutic technique developed to meet
these specific requirements in France and in different European and American countries. Its
theoretical and methodological foundations rest on the works of George Devereux in
ethnopsychiatry (1970). A psychotherapeutic technique intended for first-generation migrants
was developed by Tobie Nathan and coll (1986). Marie-Rose Moro and colleagues (1990) have
adapted this technique to second-generation migrants.
Indicated as a second-line treatment after the failure of standard management, this technique
is fully formalized today. It comprises group consultations for the child and the family as a
one-hour session each month, directed by a principal therapist, assisted by a group of
co-therapists (of diverse cultural origins and occupations) and an interpreter in the
family's mother tongue. The concept of culture is used to establish the therapeutic alliance,
decode the symptoms, and propose treatment.
The children and adolescents receiving this treatment have varied psychopathological
profiles, mostly involving depressive and/or anxiety disorders. Specifically, migrants'
children are especially vulnerable to depression, their psychiatric care is generally longer
and less effective than in the general population, and their rate of treatment failure
higher.
Transcultural psychotherapy has demonstrated its value in these situations in numerous
qualitative studies, but its efficacy has not yet been assessed by a method providing a high
level of evidence, such as randomized controlled trials.
Status | Not yet recruiting |
Enrollment | 80 |
Est. completion date | October 2023 |
Est. primary completion date | October 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 20 Years |
Eligibility |
Inclusion Criteria: - Be a child aged or an adolescent aged 6-20 years-old (this may be a declaratory age at the time of the consultation or based on a document for a residence request if no other identity documents are available) - Be a first or second-generation migrant (born abroad or born from at least one parent who is born abroad) - Have a psychological and/or psychiatric follow-up by a first-line care - Have been referred for transcultural psychotherapy by their first line care to treat depression resistant to standard management. - Present a depression according to the clinician who proposes the transcultural treatment (first line therapist), based on usual as well as cultural symptoms criteria of the below list: - Sadness - Diminish interest or pleasure in most of the usual activities - Insomnia or hypersomnia - Psychomotor agitation - Asthenia, loss of energy - Feeling of worthlessness or excessive guilt - Recurrent throughs of death - School problems (school failure, drop in grades, aggressivity with adult, school refusal…) - Mutism, and selective mutism - Runaways - Aggressivity - Impulsivity - Violence and delinquency - Conflicts with parents and adults from the community - Exclusion from family - Somatic pains - Massive separation anxiety - Regressive symptoms - loosing of an already acquired function such as speech, walk, stay alone for a sufficient time in relation to age, manage stress or anxiety for reasonable situations… - Denial of medical care for a chronic disease with no evident reasons - Cultural designation such as possessed by a spirit, being a child witch, or other cultural designations - State of trance The list is not exhaustive, and some other symptoms may be accepted if the first line clinician as well as the referent agree. The patients will be well characterized after inclusion. - Present a score >= 4 on the iCGI - Severity at inclusion. - Present transcultural issues confirmed by the referent (usual procedure of indirect pre-selection based on the presentation of the situation by referring physician) - Have an informed consent signed by both parents/ one parent / tutor / adult patient (cf. 14.1 paragraph) Exclusion Criteria: - Patient or family has previously had transcultural psychotherapy - Patient presents an acute psychiatric disorder which hinders the realization of the transcultural therapy - for example, excited delirium with great psychic disorganization, or high suicidal risk patients. These situations will be excluded during the screening time based on the first line therapist evaluation - Patient presents an acute somatic disease which may hinder the well organization of the therapy - Patient addressed for a legal expertise - Child's/Adolescent's refusal - Pregnant or breastfeeding (for women for young women of childbearing age) - Participation in another interventional study - Patient under guardianship or curatorship |
Country | Name | City | State |
---|---|---|---|
France | Service de Psychopathologie de l'enfant, de l'adolescent, CHU Avicenne | Bobigny | |
France | Service de médecine interne, unité de consultation transculturelle, CHRU Saint-André (CHU Bordeaux) | Bordeaux | |
France | Service de psychiatrie de l'enfant et de l'adolescent, CHRU Gabriel Montpied | Clermont-Ferrand | |
France | Maison de Solenn, Cochin Hospital | Paris | |
France | Secteur 75G23, Centre Médico-psychologique (CMP), GHU PARIS, Maison blanche | Paris | |
France | Centre Médico-psychologique, Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Hôpital La Grave, CHU Toulouse | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | Institut National de la Santé Et de la Recherche Médicale, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Severity Score on the Improved Global Impression Scale (iCGI) to assess remission | .iCGI score is a scale ranging from 1 to 7, 1 being Normal, not at all ill, and 7 - Among the most extremely ill patients. - Normal, not at all ill - Borderline mentally ill - Mildly ill - Moderately ill - Markedly ill - Severely ill - Among the most extremely ill patients Remission is defined as a mean iCGI score over the 3 experts <4 at 28 weeks of treatment (W34). |
at week 34 visit (v5) | |
Secondary | Severity score on the iCGI | To compare the course of the severity of depression in each group over the first 34 weeks after inclusion | at baseline and weeks 6, 13, 20, 27 and 34 and 52 | |
Secondary | Score on the French version of the Children's Depression Rating Scale-Revised (CDRS-R) | It's a 17-item scale with answers on 5 or 7-point Likert scale (total score ranges from 17 to 113). A score = 40 is indicative of depression, whereas a score =28 is often used to define remission. To compare the course of the level of depressive symptoms in each group over the first 34 weeks after inclusion |
at baseline and weeks 6, 13, 20, 27 and 34 and 52 | |
Secondary | Score on the French version of the State-Trait Anxiety Inventory for children (STAI-C) | To compare the course of the level of anxiety symptoms in each group over the first 34 weeks after inclusion | at baseline and weeks 6, 13, 20, 27 and 34 and 52 | |
Secondary | Score changes in Depression and anxiety Scores between Week 34 and week 52 | To evaluate the persistence of the efficacy of transcultural psychiatry over time by describing the course of the severity of the depression and of the depressive and anxiety symptoms from 34 to 52 weeks after inclusion in the group of patients treated by transcultural psychotherapy during the first 34 weeks | at 34 and 52 weeks | |
Secondary | analysis of the content of the clinical data collected during the visits | To describe the therapeutic processes that enabled the improvement of patients treated by transcultural psychotherapy | between 34 and 44 weeks | |
Secondary | analysis of the content of the interview with the families and therapists at the end of the treatment | For this secondary objective concerning the group of patients treated by transcultural psychotherapy, a qualitative design will be used to explore the perceived efficacity and acceptability of the therapy. Investigators will organize two semi-structured interviews after the fifth therapy session. These semi-structured interviews will be conducted by a psychologist trained in transcultural care. One interview will concern the family and will explore, with the help of an interpreter speaking the native language of the family, the acceptability of the care as well as success factors identified by the family. The other interview will concern the therapists and will explore the success factors identified by the professionals. The interviews guides have been constructed by specialists of transcultural care in childhood and adolescence To describe the perceived efficacy and acceptability of the transcultural psychotherapy for the patient and the family | between 34 and 44 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |